Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying MET-driver alterations, and effective for overcoming MET-amplification dependent resistance to EGFR therapies in EGFR-positive non-small cell lung cancer

FOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, presented two posters at the 2024 American Association for Cancer Research (AACR) Annual Meeting, held April 5-10, 2024 in San Diego, Calif. Copies of the posters are available on the Apollomics website at ir.apollomicsinc.com/news-events/presentations.

“Vebreltinib’s selectivity and high in vivo potency against multiple tumor types in a variety of patient-derived tumor models demonstrate its potential to treat a variety of MET-altered tumors, as a single agent or in combination,” said Guo-Liang Yu, PhD, Chairman and Chief Executive Officer of Apollomics. “Based on preclinical models established from patients, we believe vebreltinib may also provide meaningful clinical benefit towards overcoming or preventing MET-amplification dependent resistance in EGFR-positive non-small cell lung cancer (NSCLC) patients.”

The first poster presented, titled, “Vebreltinib: A novel brain-penetrating MET kinase inhibitor demonstrates the mechanism of action and pharmacological anti-tumor activity in diverse patient-derived MET-dysregulated tumor models at clinically relevant drug levels,” demonstrated that vebreltinib is a novel potent and selective MET kinase inhibitor showing promising preclinical activity against patient-derived tumors from diverse organ sites and genomic alterations such as MET exon 14 skipping, MET fusion, MET amplification, or MET and hepatocyte growth factor over-expression at clinically relevant drug levels, providing proof-of-concepts for continued clinical development.

The second poster presented, titled, “Dependence of EGFR-mutant NSCLC on MET as demonstrated by vebreltinib, a novel and selective brain-penetrating MET kinase inhibitor,” demonstrated that adding vebreltinib to EGFR therapies overcomes MET-amplification dependent resistance with durable effect or prevents MET-dependent resistance to maximize therapeutic benefits.

About vebreltinib (APL-101)

Vebreltinib is a potent, small molecule, orally bioavailable, brain penetrating and highly selective c-MET inhibitor. It works by inhibiting the aberrant activation of the HGF/MET axis, a key pathway involved in tumor growth, proliferation, and the development of resistance to certain targeted therapies such as osimertinib. By targeting MET dysregulation, vebreltinib offers a potential breakthrough for many cancers driven by MET alterations.